Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiLLI lower limb immobilisation thromboprophylaxis trial
ISRCTN13806452Phase 3Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Oct 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of enoxaparin, tinzaparin, dalteparin, fondaparinux, rivaroxaban and 1 more in venous thromboembolism (VTE) (5 arms), sponsored by Queen Mary University of London. Primary endpoint: Composite net clinical benefit. Started Oct 2024; status: recruiting.
02
Drugs
enoxaparintinzaparindalteparinfondaparinuxrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ISRCTN13806452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13806452.